Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib Plus Defactinib vs Investigator's Choice in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781Phase 3Recruiting
- Sponsor
- Verastem Oncology
- Start
- Mar 2024
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of avutometinib and defactinib in Low grade serous ovarian cancer (LGSOC) (2 arms), sponsored by Verastem Oncology. Primary endpoint: Progression-Free Survival at 24 months. Started Mar 2024; status: recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
Low grade serous ovarian cancer (LGSOC)
Beyond the preview
Go deeper on NCT06072781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072781.